Investigational drug · Phase 3
PF-08634404
Also called: SSGJ-707
Not approved by FDA. In 12 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
12
12 still active
All registered trials
11
Any phase or sponsor naming "PF-08634404"
First trial start
2024
Sep 3, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
- Pfizer11
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PF-08634404", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Small Cell Lung Cancer (SCLC)
- Carcinoma, Hepatocellular
- Hepatocellular Cancer
- Hepatocellular Carcinoma
- Unresectable Hepatocellular Carcinoma
- Liver Neoplasms
- Advanced Hepatocellular Carcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "PF-08634404" as an intervention, largest first.
- Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07222566 · 1,410 participants (planned) · Start Jan 6, 2026 · Primary completion Feb 27, 2029
Drug: PF-08634404; Pembrolizumab and 2 more · For: Advanced Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung and 3 more
Sites: Bullhead City, Arizona; Chandler, Arizona; Gilbert, Arizona · 484 sites in all
- Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07392892 · 840 participants (planned) · Start May 14, 2026 · Primary completion Jul 22, 2031
Drug: PF-08634404; Chemotherapy and 1 more · For: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma; Metastatic Gastric Cancer; Gastroesophageal Junction Cancer and 1 more
Sites: Atascadero, California; Burbank, California; Encino, California · 102 sites in all
- Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07222800 · 800 participants (planned) · Start Dec 11, 2025 · Primary completion Feb 23, 2030
Drug: PF-08634404; Bevacizumab and 1 more · For: Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms and 7 more
Sites: Chandler, Arizona; Gilbert, Arizona; Glendale, Arizona · 372 sites in all
- Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07578649 · 600 participants (planned) · Start Oct 14, 2026 · Primary completion Jun 1, 2029
Drug: PF-08634404; Pembrolizumab and 1 more · For: Endometrial Neoplasms; Endometrial Cancer
Sites: Jupiter, Florida; Orlando, Florida; Coon Rapids, Minnesota · 54 sites in all
PfizerPfizer (PFE)
NCT07226999 · 550 participants (planned) · Start Dec 9, 2025 · Primary completion Jun 14, 2030
Drug: PF-08634404; Tarlatamab and 2 more · For: Small Cell Lung Cancer (SCLC)
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 85 sites in all
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07227415 · 224 participants (planned) · Start Feb 10, 2026 · Primary completion Nov 2, 2027
Drug: PF-08634404; Ipilimumab and 2 more · For: Carcinoma, Renal Cell; Advanced Renal Cell Carcinoma; Renal Cancer and 10 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fayetteville, Arkansas · 183 sites in all
PfizerPfizer (PFE)
NCT07227298 · 162 participants (planned) · Start Jan 30, 2026 · Primary completion Mar 8, 2029
Drug: PF-08634404; Sigvotatug Vedotin and 1 more · For: Advanced/Metastatic Non-Small Cell Lung Cancer; Carcinoma, Non-Small Cell Lung; Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 104 sites in all
PfizerPfizer (PFE)
NCT07227012 · 138 participants (planned) · Start Dec 1, 2025 · Primary completion Oct 18, 2027
Drug: PF-08634404; Ipilimumab · For: Carcinoma, Hepatocellular; Hepatocellular Cancer; Hepatocellular Carcinoma and 4 more
Sites: Irvine, California; Los Angeles, California; Orange, California · 60 sites in all
PfizerPfizer (PFE)
NCT07421700 · 132 participants (planned) · Start Mar 11, 2026 · Primary completion Dec 28, 2027
Drug: PF-08634404; Enfortumab Vedotin · For: Urothelial Cancer; Advanced/Metastatic Urothelial Cancer; Urothelial Carcinoma
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 184 sites in all
PfizerPfizer (PFE)
NCT07489066 · 120 participants (planned) · Start Jun 30, 2026 · Primary completion Jul 29, 2028
Drug: PF-08634404; Chemotherapy Regimen 1 and 1 more · For: Carcinoma; Non-Small-Cell Lung; Lung Cancer (NSCLC) and 6 more
Sites: Huntsville, Alabama; Stanford, California; Athens, Georgia · 37 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- PD-(L)1×VEGF bispecific antibodies in solid tumors: clinical trial updates from ASCO 2026.
Wang Z, Guo C, Yuan X, et al. · J Hematol Oncol 2026
- Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.
Rini BI, Garmezy B · Oncol Ther 2026
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.